Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Julia Boshuizen, Nora Pencheva, Oscar Krijgsman, Daniela D'Empaire Altimari, Patricia Garrido Castro, Beaunelle de Bruijn, Maarten A. Ligtenberg, Elke Gresnigt-Van den Heuvel, David W. Vredevoogd, Ji-Ying Song, Nils Visser, Georgi Apriamashvili, Maarten L. Janmaat, Theo S. Plantinga, Patrick Franken, Mischa Houtkamp, Andreas Lingnau, Maria Jure-Kunkel, Daniel S. Peeper

Cancer Res (2021) 81 (7): 1775–1787.

https://doi.org/10.1158/0008-5472.CAN-20-0434

Published: 01 April 2021

View articletitled, Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Includes: Supplementary data

Journal Articles

Abstract 4544: Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models

Laurens P. Kil, Simone C. Oostindie, Kristin Strumane, Hilma J. van der Horst, Berris van Kessel, Marije B. Overdijk, Andreas Lingnau, Marcel Brandhorst, Jeroen van den Brakel, Margaret A. Lindorfer, Ronald P. Taylor, Martine E. Chamuleau, Tuna Mutis, A. Kate Sasser, Janine Schuurman, Paul W. Parren, Frank J. Beurskens, Esther C. Breij

Cancer Res (2020) 80 (16_Supplement): 4544.

https://doi.org/10.1158/1538-7445.AM2020-4544

Published: 15 August 2020

View articletitled, Abstract 4544: Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models

Journal Articles

Abstract 2391: DR5 agonist activity of HexaBody^®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models

Marije B. Overdijk, Kristin Strumane, Antonio Ortiz Buijsse, Claudine Vermot-Desroches, Thessa Kroes, Bart de Jong, Naomi Hoevenaars, Frank J. Beurskens, Rob N. de Jong, Andreas Lingnau, Paul W. Parren, Ulf Forssmann, A Kate Sasser, Janine Schuurman, Esther C. Breij

Cancer Res (2019) 79 (13_Supplement): 2391.

https://doi.org/10.1158/1538-7445.AM2019-2391

Published: 01 July 2019

View articletitled, Abstract 2391: DR5 agonist activity of HexaBody®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models

Journal Articles

Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC

Louise A. Koopman, Maarten L. Janmaat, Kirstine Jacobsen, Mikkel Green Terp, Elke Gresnigt-van den Heuvel, Ulf Forssman, Andreas Lingnau, Paul W. Parren, Henrik Ditzel, Esther C. Breij

Cancer Res (2018) 78 (13_Supplement): 832.

https://doi.org/10.1158/1538-7445.AM2018-832

Published: 01 July 2018

View articletitled, Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC

Journal Articles

Abstract 592: Improving therapeutic activity of agonistic DR5 antibodies by inducing target binding-dependent hexamer formation

Marije B. Overdijk, Kristin Strumane, Antonio Ortiz Buijsse, Claudine Vermot-Desroches, Andreas Lingnau, Esther C.W. Breij, Janine Schuurman, Paul W.H.I. Parren

Cancer Res (2016) 76 (14_Supplement): 592.

https://doi.org/10.1158/1538-7445.AM2016-592

Published: 15 July 2016

View articletitled, Abstract 592: Improving therapeutic activity of agonistic DR5 antibodies by inducing target binding-dependent hexamer formation

Journal Articles

Abstract 634: Novel antibody-drug conjugates targeting Axl show anti-tumor activity in solid cancer xenograft models

Esther C.W. Breij, Sandra Verploegen, Andreas Lingnau, Edward N. van den Brink, Maarten Janmaat, Mischa Houtkamp, Wim K. Bleeker, David Satijn, Paul W.H.I. Parren

Cancer Res (2015) 75 (15_Supplement): 634.

https://doi.org/10.1158/1538-7445.AM2015-634

Published: 01 August 2015

View articletitled, Abstract 634: Novel antibody-drug conjugates targeting Axl show anti-tumor activity in solid cancer xenograft models

Journal Articles

Abstract 1222: Establishment of a reliable metastasizing syngeneic breast cancer mouse model using orthotopically implanted 4T1 cells after several rounds of isolating and reimplanting lung metastases

Andreas Lingnau, Steffen Hoffmann, Sandra Moor, Cynthia Schaefer-Obodozie, Christoph Schaechtele

Cancer Res (2014) 74 (19_Supplement): 1222.

https://doi.org/10.1158/1538-7445.AM2014-1222

Published: 01 October 2014

View articletitled, Abstract 1222: Establishment of a reliable metastasizing syngeneic breast cancer mouse model using orthotopically implanted 4T1 cells after several rounds of isolating and reimplanting lung metastases

Journal Articles

Abstract 1554: Inducible B-Raf and c-Src models as tools for drug development.

Jan E. Ehlert, Bettina Mutschler, Melanie Mueller, Andreas Lingnau, Steffen Hoffmann, Holger Weber, Michael H. G. Kubbutat

Cancer Res (2013) 73 (8_Supplement): 1554.

https://doi.org/10.1158/1538-7445.AM2013-1554

Published: 15 April 2013

View articletitled, Abstract 1554: Inducible B-Raf and c-Src models as tools for drug development.

Journal Articles

Abstract 2788: Characterization of an in vivo generated subpopulation of human LnCaP prostate cancer cells as an improved testosterone-dependent in vivo mouse xenograft model for compound testing.

Andreas Lingnau, Steffen Hoffmann, Cynthia Schaefer-Obodozie, Ulrike Leisegang, Andreas Klotzbuecher, Christoph Schaechtele

Cancer Res (2013) 73 (8_Supplement): 2788.

https://doi.org/10.1158/1538-7445.AM2013-2788

Published: 15 April 2013

View articletitled, Abstract 2788: Characterization of an in vivo generated subpopulation of human LnCaP prostate cancer cells as an improved testosterone-dependent in vivo mouse xenograft model for compound testing.

Journal Articles

Abstract 2363: Comparison and characterization of two orthotopic glioblastoma in vivo mouse models with human U87 and LN-229 cells using in vivo bioluminescence imaging and magnetic resonance imaging (MRI)

Andreas Lingnau, Steffen Hoffmann, Claudia Weidensteiner, Wilfried Reichardt, Fabian Kording, Cynthia Obodozie-Schaefer, Christoph Schaechtele

Cancer Res (2012) 72 (8_Supplement): 2363.

https://doi.org/10.1158/1538-7445.AM2012-2363

Published: 15 April 2012

View articletitled, Abstract 2363: Comparison and characterization of two orthotopic glioblastoma in vivo mouse models with human U87 and LN-229 cells using in vivo bioluminescence imaging and magnetic resonance imaging (MRI)

Journal Articles

Abstract 1609: In vivo and ex vivo comparison of two human AML bone marrow engraftment mouse models using fire fly luciferase expressing MOLM-13 and MV4-11 cells

Andreas Lingnau, Daniel Feger, Steffen Hoffmann, Sarah Umber, Michael HG Kubbutat

Cancer Res (2011) 71 (8_Supplement): 1609.

https://doi.org/10.1158/1538-7445.AM2011-1609

Published: 15 April 2011

View articletitled, Abstract 1609: In vivo and ex vivo comparison of two human AML bone marrow engraftment mouse models using fire fly luciferase expressing MOLM-13 and MV4-11 cells

Journal Articles

Abstract 3225: Cellular and in vivo models for the analyses of B-Raf and c-Src inhibitors

Jan E. Ehlert, Bettina Mutschler, Melanie Müller, Andreas Lingnau, Steffen Hoffmann, Michael HG Kubbutat

Cancer Res (2010) 70 (8_Supplement): 3225.

https://doi.org/10.1158/1538-7445.AM10-3225

Published: 15 April 2010

View articletitled, Abstract 3225: Cellular and in vivo models for the analyses of B-Raf and c-Src inhibitors

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Abstract 4544: Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models

Abstract 2391: DR5 agonist activity of HexaBody^®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models

Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC

Abstract 592: Improving therapeutic activity of agonistic DR5 antibodies by inducing target binding-dependent hexamer formation

Abstract 634: Novel antibody-drug conjugates targeting Axl show anti-tumor activity in solid cancer xenograft models

Abstract 1222: Establishment of a reliable metastasizing syngeneic breast cancer mouse model using orthotopically implanted 4T1 cells after several rounds of isolating and reimplanting lung metastases

Abstract 1554: Inducible B-Raf and c-Src models as tools for drug development.

Abstract 2788: Characterization of an in vivo generated subpopulation of human LnCaP prostate cancer cells as an improved testosterone-dependent in vivo mouse xenograft model for compound testing.

Abstract 2363: Comparison and characterization of two orthotopic glioblastoma in vivo mouse models with human U87 and LN-229 cells using in vivo bioluminescence imaging and magnetic resonance imaging (MRI)

Abstract 1609: In vivo and ex vivo comparison of two human AML bone marrow engraftment mouse models using fire fly luciferase expressing MOLM-13 and MV4-11 cells

Abstract 3225: Cellular and in vivo models for the analyses of B-Raf and c-Src inhibitors

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only